Compare Innodata Inc (INOD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innodata Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Innodata Inc trades at $63.82 (market cap $2.03B), while State Street SPDR S&P Biotech ETF trades at $154.41. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Innodata Inc nearer its low. Which is the better fit depends on your goals.
| INOD | XBI | |
|---|---|---|
Market Cap | $2.03B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $121.50 | $164.28 |
52-Week Low | $34.45 | $85.16 |
Enterprise Value | $1.91B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INOD trades at $62.08, up 2.09% today, but faces bearish technical signals with 17 sell indicators. The stock has demonstrated strong fundamental performance with three consecutive earnings beats and robust profitability metrics including 38.57% ROE and 13.86% net margin. Recent news highlights the company's AI-driven growth momentum with a 40%+ outlook and expanding Big Tech partnerships.
Despite rich valuations (P/E 55.43), INOD's AI expansion and raised guidance present growth potential, though customer concentration and technical weakness pose risks. Analyst consensus remains bullish with a $130 price target representing 109% upside, supported by accelerating revenue growth and margin expansion in the AI services sector.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
